The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease

Ian James Martins

Research output: Contribution to journalEditorialpeer-review

56 Downloads (Pure)


Diagnostic technologies for biomarker analysis have become important to the immune system and mitophagy to prevent early programmed cell death. Projected costs for biomarker analysis is expected to increase to billions of dollars in the next few years but altered biological and cell membrane interactions may not allow early diagnosis of immune system dysfunction related to early progression of global organ disease. In the developing world LPS and xenobiotic levels may be responsible for altered biological interactions and supersede diagnositic technologies for biomarker analysis. Inactivation of Sirt 1 by increased ceramide levels and nutritional disturbances may be responsible for increased inflammation (autoimmune disease) and mitophagy in NAFLD and global chronic disease.
Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalInternational Journal of Microbiology & Infectious Diseases
Issue number1
Publication statusPublished - 12 Jul 2017


Dive into the research topics of 'The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease'. Together they form a unique fingerprint.

Cite this